Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
- Liang Feng†1, 2,
- Hang-Ping Yao†1, 2,
- Sharad Sharma2,
- Yong-Qing Zhou3,
- Jianwei Zhou4,
- Ruiwen Zhang5 and
- Ming-Hai Wang1, 2Email author
https://doi.org/10.1186/s13046-016-0364-5
© The Author(s). 2016
Received: 25 May 2016
Accepted: 25 May 2016
Published: 17 June 2016
The original article was published in Journal of Experimental & Clinical Cancer Research 2016 35:70
Erratum
Unfortunately, the original version of this article [1] contained an error. The name of one of the authors, Sharad Sharma, was not included in the author list.
The correct author list and the new “Authors’ contributions” section have been correctly included in full in this erratum and updated in the original article.
Notes
Declarations
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
References
- Feng L, Yao HP, Sharma S, Zhou YQ, Zhou J, Zhang R, et al. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. J Exp Clin Cancer Res. 2016;35(1):70. doi:10.1186/s13046-016-0347-6.View ArticlePubMedPubMed CentralGoogle Scholar
